{"entity":{"id":"trop2-pet-to-adc","kind":"pairing","name":"TROP2 PET → TROP2 ADC selection","aka":[],"tldr":"Proposed: a TROP2 PET scan to choose between three TROP2 ADCs and predict who will respond, since tissue staining has not worked.","summary":"This proposed diagnostic-therapeutic pairing uses TROP2 PET to choose among the TROP2 Antibody-drug conjugate (ADC) agents Sacituzumab govitecan, Datopotamab deruxtecan and Sacituzumab tirumotecan and to predict who will respond, since tissue staining has not worked. The rationale is that ASCENT showed benefit regardless of TROP2 immunohistochemistry, possibly because one archival sample misses heterogeneity and dynamics that whole-body PET could capture. First-in-human TROP2 tracers exist (89Zr antibodies, 68Ga and 18F nanobodies) but there are no outcome data yet, so the evidence is concept plus phase 1 imaging. It would also allow monitoring of antigen loss on progression and rational ADC sequencing in Triple-negative breast cancer (TNBC) and Non-small-cell lung cancer.","asOf":"2026-09-04","links":[],"tags":[],"related":["idea-trop2-pet-selection"],"cancers":["tnbc","nsclc"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["sacituzumab-govitecan","datopotamab-deruxtecan","sacituzumab-tirumotecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"a":"trop2-pet","b":"adc","rationale":"ASCENT showed benefit regardless of IHC TROP2, possibly because IHC on one archival sample misses heterogeneity and dynamics; whole-body PET could capture both.","evidence":"Concept; phase 1 imaging studies.","pairingType":"diagnostic-therapeutic"},"route":"/pairings/trop2-pet-to-adc/","neighbours":{"idea":[{"id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/"}],"roadmap":[{"id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/"},{"id":"trop2-adc-roadmap","kind":"roadmap","name":"TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET","route":"/roadmaps/trop2-adc-roadmap/"}]}}